• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is Ketamine Just Another Opiate?

Is Ketamine Just Another Opiate?

January 1, 2019
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Williams NR et al, Am J Psychiatry 2018;175:1–11

Type of study: Double-blind, placebo-controlled, crossover study

Ketamine’s rapid antidepressant effects have now been demonstrated in over two dozen double-blind, placebo-controlled trials, but how it works is less clear. For many years, NMDA receptor antagonism was thought responsible, but other NMDA antagonists have not worked well in depression. Another possibility is the endogenous opioid system, which is responsible for ketamine’s analgesic effects. If that system is also involved in ketamine’s antidepressant effects, then the opioid antagonist naltrexone ought to interfere with those benefits. This study sought to determine whether naltrexone would in fact dampen ketamine’s benefits in depression.

Thirty subjects with chronic, highly refractory depression were enrolled (with a mean of 9.8 unsuccessful antidepressant trials). Each participant received, in random order, 2 separate IV infusions of ketamine 0.5 mg/kg—one preceded by naltrexone 50 mg and the other preceded by placebo. The primary outcome was reduction in depressive symptoms at postinfusion day 1. The dissociative effects of ketamine were examined as well.

When ketamine was given with a placebo, the response (58%) and remission (42%) rates for depression were high, but coadministration with naltrexone brought those rates to zero. In contrast, naltrexone did not have any discernible impact on ketamine’s dissociative effects. Data collected on blinding suggested that participants were unable to discern when they were receiving naltrexone vs placebo.

The results were dramatic enough that the study was halted midway through for ethical reasons, so only 12 of the 30 subjects completed both arms.

TCPR’s Take
Could ketamine be nothing more than an opiate masquerading as an NMDA receptor antagonist? While the opioid system appears critical to ketamine’s antidepressant effects, that doesn’t mean ketamine directly affects opioid receptors in the way that morphine or codeine does. Endogenous opioids have well-known mood elevating properties, and exercise and even placebo stimulate endogenous opioids. Given the public health crises stemming from both treatment-refractory depression and opioid abuse, this study will no doubt stimulate a flurry of research into the exact role that the opioid system plays. Perhaps ketamine will unlock some of the mysteries behind the mechanisms of ­antidepressants.
General Psychiatry
KEYWORDS antidepressants depression ketamine opioids research-update
    Michael Posternak, MD.

    Psychological Benefits of Abstaining from Social Media

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Deprescribing, TCPR, January 2019
    Brexanolone: A New Treatment for Postpartum Depression
    Is Ketamine Just Another Opiate?
    Cannabidiol for Schizophrenia
    Wellbutrin Augmentation: When Does It Work?
    Deprescribing Medication
    Prescription CBD Is Available, But Are We Ready to Use It?
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.